SGLT1 inhibition in cystic fibrosis: From preclinical evidence to clinical potential.

Xiubin Liang, Yang Liu, Shijing Jia, Kezhong Zhang, Jie Xu

Abstract readReview

In one paragraph

Review in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiubin LiangCenter for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

Yang LiuCenter for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

Shijing JiaDivision of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

Kezhong ZhangCenter for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI 48201, USA.

Jie XuCenter for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

Funding

Targeting SGLTs for liver disease in a rabbit model of cystic fibrosisR01DK134361 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JIE XU, Kezhong Zhang · 2023 to 2026

$2.5M

Iron Deficiency in Cystic Fibrosis: Characterization of Clinical Impact and Treatment EffectsK23HL175126 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Shijing Jia · 2025 to 2026

$390k

NHLBI NIH HHS K23 HL175126NIDDK NIH HHS R01 DK134361

6 · The paper itself

Abstract

Cystic fibrosis (CF) is a life-threatening autosomal recessive disease caused by loss-of-function mutations in the CF transmembrane conductance regulator (

Indexed as

CF hepatobiliary involvementCF-related diabetescystic fibrosisSGLT inhibitorssodium-glucose cotransporters

Identifiers

PMID42999678

DOI10.1016/j.omta.2026.201868

PMCPMC13743517

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.